AKI was associated with a higher HR for death in patients with de novo AML, favorable ELN2022 risk and wildtype ASXL1, FLT3-ITD, IDH1, IDH2, and RUNX1 (Figure S4). This evidence concerns the gene IDH2 and acute myeloid leukemia.